Lipoprotein Metabolism and Lipid Management in Chronic Kidney Disease
The DOI matches its Crossref record; 140 of the 141 references it cites were found in a registry or an index.
Abstract
Dyslipidemia is an established cardiovascular (CV) risk factor in the general population. In chronic kidney disease (CKD), however, epidemiologic studies ([1][1]–[3][2]) and clinical trials ([4][3]–[12][4]) have raised uncertainties regarding the impact of dyslipidemia on clinical outcomes and,
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Chronic kidney disease is characterized by mixed dyslipidaemia (high triglycerides, high LDL cholesterol, and low HDL cholesterol).492”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [492]
Citations
Cites
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
LIPOPROTEIN METABOLISM IN THE MACROPHAGE: Implications for Cholesterol Deposition in Atherosclerosis
Brown, M. S., & Goldstein, J. L. (1983) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.52.070183.001255 · Cited by 2,300
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor
Acton, S., Rigotti, A., Landschulz, K. T., Xu, S., Hobbs, H. H., & Krieger, M. (1996) · Science · doi:10.1126/science.271.5248.518 · Cited by 2,026
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Lowrie, E. G., & Lew, N. L. (1990) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)70364-5 · Cited by 1,976
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure
Stenvinkel, P., Heimbürger, O., Paultre, F., Diczfalusy, U., Wang, T., Berglund, L., & Jogestrand, T. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00422.x · Cited by 1,778
Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
Zimmermann, J., Herrlinger, S., Pruy, A., Metzger, T., & Wanner, C. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00273.x · Cited by 1,531
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients
Chertow, G. M., Burke, S. K., Raggi, P., & for the Treat to Goal Working Group (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00434.x · Cited by 1,462
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411
Boaz, M., Smetana, S., Weinstein, T., Matas, Z., Gafter, U., Iaina, A., Knecht, A., Weissgarten, Y., Brunner, D., Fainaru, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02783-5 · Cited by 1,025
Taylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890
Drug Treatment of Lipid Disorders
Knopp, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410707 · Cited by 845
Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis
Block, G. A., Spiegel, D. M., Ehrlich, J., Mehta, R., Lindbergh, J., Dreisbach, A., & Raggi, P. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00600.x · Cited by 815
Liu, Y., Coresh, J., Eustace, J. A., Longenecker, J. C., Jaar, B., Fink, N. E., Tracy, R. P., Powe, N. R., & Klag, M. J. (2004) · JAMA · doi:10.1001/jama.291.4.451 · Cited by 777
Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients
Cheung, A. K., Sarnak, M. J., Yan, G., Dwyer, J. T., Heyka, R. J., Rocco, M. V., Teehan, B. P., & Levey, A. S. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00173.x · Cited by 777
Self-citationCarlson, L. A., & ROSENHAMER, G. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb15891.x · Cited by 677
Longenecker, J. C., Coresh, J., Powe, N. R., Levey, A. S., Fink, N. E., Martin, A., & Klag, M. J. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000019641.41496.1e · Cited by 594
Scavenger Receptors in Atherosclerosis: Beyond Lipid Uptake
Moore, K. J., & Freeman, M. W. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000229218.97976.43 · Cited by 562
Mortality Risk Factors in Patients Treated by Chronic Hemodialysis
Degoulet, P., Legrain, M., Réach, I., Aimé, F., Devriès, C., Rojas, P., & Jacobs, C. (1982) · Nephron · doi:10.1159/000182627 · Cited by 529
Risk for Myopathy With Statin Therapy in High-Risk Patients
Ballantyne, C. M., Corsini, A., Davidson, M. H., Holdaas, H., Jacobson, T. A., Leitersdorf, E., März, W., Reckless, J. P. D., & Stein, E. A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.5.553 · Cited by 453
Diabetes Mellitus, Aortic Stiffness, and Cardiovascular Mortality in End-Stage Renal Disease
SHOJI, T., EMOTO, M., SHINOHARA, K., KAKIYA, R., TSUJIMOTO, Y., KISHIMOTO, H., ISHIMURA, E., TABATA, T., & NISHIZAWA, Y. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v12102117 · Cited by 450
CARLSON, L. A., HAMSTEN, A., & ASPLUND, A. (1989) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1989.tb01393.x · Cited by 443 · cited 1×
“It is very effective in raising plasma HDL cholesterol level and is the only drug available to lower plasma Lp(a) substantially (119).”
BackgroundHypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients
Iseki, K., Yamazato, M., Tozawa, M., & Takishita, S. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00324.x · Cited by 383
Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease
Tonelli, M., Isles, C., Curhan, G. C., Tonkin, A., Pfeffer, M. A., Shepherd, J., Sacks, F. M., Furberg, C., Cobbe, S. M., Simes, J., et al. (2004) · Circulation · doi:10.1161/01.cir.0000143892.84582.60 · Cited by 381
Tissue lipoprotein lipase activity and its action in lipoprotein metabolism
Cryer, A. (1981) · International Journal of Biochemistry · doi:10.1016/0020-711x(81)90177-4 · Cited by 369
Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV.
Steinmetz, A., & Utermann, G. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)89547-3 · Cited by 341
On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein
Eisenberg, S., Bilheimer, D. W., Levy, R. I., & Lindgren, F. T. (1973) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(73)90138-0 · Cited by 335
Study of Heart and Renal Protection (SHARP)
Baigent, C., & Landry, M. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s84.4.x · Cited by 320
HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients
Seliger, S. L., Weiss, N. S., Gillen, D. L., Kestenbaum, B., Ball, A., Sherrard, D. J., & Stehman-Breen, C. O. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00109.x · Cited by 294
Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV.
Goldberg, I. J., Scheraldi, C. A., Yacoub, L. K., Saxena, U., & Bisgaier, C. L. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39557-2 · Cited by 291
Lipid abnormalities in renal disease
Appel, G. (1991) · Kidney International · doi:10.1038/ki.1991.22 · Cited by 286
Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin.
Harpel, P. C., Gordon, B. R., & Parker, T. S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3847 · Cited by 285
Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients.
Cressman, M. D., Heyka, R. J., Paganini, E. P., O'Neil, J., Skibinski, C. I., & Hoff, H. F. (1992) · Circulation · doi:10.1161/01.cir.86.2.475 · Cited by 281
Tonelli, M., Moy, L., Sacks, F. M., Kiberd, B., Curhan, G., & for the Cholesterol and Recurrent Events (CARE) Trial Investigators (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-2-200301210-00010 · Cited by 278 · cited 1×
“This concern was not substantiated by the 4D study (12) and most other large studies (7,10,11).”
ResultMcNamara, J. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00484-6 · Cited by 278
PLASMA LIPID TRANSFER PROTEINS, HIGH-DENSITY LIPOPROTEINS, AND REVERSE CHOLESTEROL TRANSPORT
Bruce, C., Chouinard, R. A., & Tall, A. R. (1998) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.18.1.297 · Cited by 258
KRONENBERG, F., KUEN, E., RITZ, E., JUNKER, R., KO[Combining Diaeresis]NIG, P., KRAATZ, G. D., LHOTTA, K., MANN, J. F. E., MU[Combining Diaeresis]LLER, G. A., NEYER, U., et al. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v111105 · Cited by 248
Self-citationTatami, R., Mabuchi, H., Ueda, K., Ueda, R., Haba, T., Kametani, T., Ito, S., Koizumi, J., Ohta, M., Miyamoto, S., et al. (1981) · Circulation · doi:10.1161/01.cir.64.6.1174 · Cited by 246
Stein, O., Stein, Y., Lefevre, M., & Roheim, P. S. (1986) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(86)90337-1 · Cited by 240
Increased Lipoprotein-Remnant Formation in Chronic Renal Failure
Nestel, P. J., Fidge, N. H., & Tan, M. H. (1982) · New England Journal of Medicine · doi:10.1056/nejm198208053070601 · Cited by 240
Kronenberg, F., König, P., Neyer, U., Auinger, M., Pribasnig, A., Lang, U., Reitinger, J., Pinter, G., Utermann, G., & Dieplinger, H. (1995) · Journal of the American Society of Nephrology · doi:10.1681/asn.v61110 · Cited by 233
Self-citationRole of apoptosis in atherosclerosis and its therapeutic implications
STONEMAN, V. E. A., & BENNETT, M. R. (2004) · Clinical Science · doi:10.1042/cs20040086 · Cited by 220
Steinmetz, A., Barbaras, R., Ghalim, N., Clavey, V, Fruchart, J. C., & Ailhaud, G. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39010-6 · Cited by 212
STACK, A. G., & BLOEMBERGEN, W. E. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1271516 · Cited by 211
Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies
Craig, W. Y., Neveux, L. M., Palomaki, G. E., Cleveland, M. M., & Haddow, J. E. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.11.2301 · Cited by 210
New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders
McKenney, J. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.7.697 · Cited by 209
Lipoprotein abnormalities and their consequences for patients with type 2 diabetes
Krentz, A. J. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1462-8902.2003.0310.x · Cited by 205 · cited 1×
“There seems to be a gradual shift to the uremic lipid profile as kidney function deteriorates (19,20), which is further modified by concurrent illnesses such as diabetes (21) and nephrotic syndrome (22).”
BackgroundApoptotic cell death in atherosclerosis
Littlewood, T. D., & Bennett, M. R. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200310000-00007 · Cited by 194
A PROPOSED GENETIC MARKER FOR CORONARY HEART DISEASE RISK
Austin, King, M., VRANIZAN, K. M., & Krauss, R. M. (1990) · Cited by 194
Decrease of serum paraoxonase activity in chronic renal failure.
Dantoine, T. F., Debord, J., Charmes, J. P., Merle, L., Marquet, P., Lachatre, G., & Leroux-Robert, C. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v9112082 · Cited by 188
Shoji, T., Nishizawa, Y., Kawagishi, T., Kawasaki, K., Taniwaki, H., Tabata, T., Inoue, T., & Morii, H. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v971277 · Cited by 185
Attman, P.-O., & Alaupovic, P. (1991) · Nephron · doi:10.1159/000186303 · Cited by 179
Fibric acids: Effects on lipids and lipoprotein metabolism
Grundy, S. M., & Vega, G. L. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90866-7 · Cited by 175
Koch, M., Kutkuhn, B., Trenkwalder, E., Bach, D., Grabensee, B., Dieplinger, H., & Kronenberg, F. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v8121889 · Cited by 165
Self-citationDvorin, E., Gorder, N. L., Benson, D. M., & Gotto, A. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)66776-6 · Cited by 158
Mason, N. A., Bailie, G. R., Satayathum, S., Bragg-Gresham, J. L., Akiba, T., Akizawa, T., Combe, C., Rayner, H. C., Saito, A., Gillespie, B. W., et al. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.09.025 · Cited by 158
Chen, C. H., & Albers, J. J. (1985) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(85)90131-6 · Cited by 157
KRONENBERG, F., NEYER, U., LHOTTA, K., TRENKWALDER, E., AUINGER, M., PRIBASNIG, A., MEISL, T., KÖNIG, P., & DIEPLINGER, H. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1051027 · Cited by 155
Self-citationDefective Triglyceride Removal in Lipemia Associated with Peritoneal Dialysis and Haemodialysis
Cattran, D. C., FENTON, S. S. A., WILSON, D. R., & STEINER, G. (1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-85-1-29 · Cited by 152
Elevated Plasma Lipoprotein(a) in Patients with the Nephrotic Syndrome
Wanner, C., Rader, D., Bartens, W., Kramer, J., Brewer, H. B., Schollmeyer, P., & Wieland, H. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-4-199308150-00002 · Cited by 149
Dieplinger, H., Lackner, C., Kronenberg, F., Sandholzer, C., Lhotta, K., Hoppichler, F., Graf, H., & König, P. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116213 · Cited by 142
Self-citationDifferential effects of nicotinic acid in subjects with different LDL subclass patterns
Superko, H. R., & Krauss, R. M. (1992) · Atherosclerosis · doi:10.1016/0021-9150(92)90177-i · Cited by 132
Predictors of stroke in patients receiving chronic hemodialysis
Iseki, K., & Fukiyama, K. (1996) · Kidney International · doi:10.1038/ki.1996.484 · Cited by 131
Ferramosca, E., Burke, S. K., Chasan-Taber, S., Ratti, C., Chertow, G. M., & Raggi, P. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.07.023 · Cited by 131
Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease
Kronenberg, F., Stuehlinger, M., Trenkwalder, E., Geethanjali, F. S., Pachinger, O. M., von Eckardstein, A., & Dieplinger, H. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00775-0 · Cited by 130
Self-citationBest, P. J. M., Hasdai, D., Sangiorgi, G., Schwartz, R. S., Holmes, D. R., Simari, R. D., & Lerman, A. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.1.14 · Cited by 126
Risk factors for statin‐associated rhabdomyolysis
Schech, S., Graham, D., Staffa, J., Andrade, S. E., Grenade, L. L., Burgess, M., Blough, D., Stergachis, A., Chan, K. A., Platt, R., et al. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1287 · Cited by 125
Mann, J. F. E., Lonn, E., Yi, Q., Gerstein, H. C., Hoogwerf, B. J., Pogue, J., Bosch, J., Dagenais, G. R., Yusuf, S., & On Behalf Of The Cannulate Tavr Expanded Investigators (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00513.x · Cited by 124
Islam, K. N., O’Byrne, D., Devaraj, S., Palmer, B. F., Grundy, S. M., & Jialal, I. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00410-4 · Cited by 121
Yukawa, S., Hibino, A., Maeda, T., Mimura, K., Yukawa, A., Maeda, A., Kishino, M., Sonobe, M., Mune, M., Yamada, Y., et al. (1995) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/10.supp3.1 · Cited by 117
Lowrie, E. G., & Lew, N. L. (1992) · PubMed · Cited by 111
Leary, E. T., Wang, T., Baker, D. J., Cilla, D. D., Zhong, J., Warnick, G. R., Nakajima, K., & Havel, R. J. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.12.2490 · Cited by 110
Oxidized lipids as mediators of coronary heart disease
Navab, M., Hama, S. Y., Ready, S. T., Ng, C. J., Van Lenten, B. J., Laks, H., & Fogelman, A. M. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200208000-00003 · Cited by 109
Sentí, M., Romero, R., Pedro‐Botet, J., Pelegrí, A., Nogués, X., & Rubiés-Prat, J. (1992) · Kidney International · doi:10.1038/ki.1992.204 · Cited by 108
Tonelli, M. A., Collins, D. E., Robins, S. J., Bloomfield, H. E., & Curhan, G. C. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00862.x · Cited by 105
Kronenberg, F., Kathrein, H., König, P., Neyer, U., Sturm, W., Lhotta, K., Gröchenig, E., Utermann, G., & Dieplinger, H. (1994) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.14.9.1405 · Cited by 102
Self-citationIn vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients
Frischmann, M. E., Kronenberg, F., Trenkwalder, E., Schaefer, J. R., Schweer, H., Dieplinger, B., Koenig, P., Ikewaki, K., & Dieplinger, H. (2007) · Kidney International · doi:10.1038/sj.ki.5002131 · Cited by 101
Self-citationEffect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients
Mune, M., Yukawa, S., Kishino, M., Otani, H., Kimura, K., Nishikawa, O., Takahashi, T., Kodama, N., Saika, Y., & Yamada, Y. M. A. (1999) · Kidney International · doi:10.1016/s0085-2538(15)46619-0 · Cited by 94
Longenecker, C. J., Klag, M. J., Marcovina, S. M., Liu, Y.-M., Jaar, B. G., Powe, N. R., Fink, N. E., Levey, A. S., & Coresh, J. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004110922 · Cited by 94
Kronenberg, F., König, P., Lhotta, K., Ofner, D., Sandholzer, C., Margreiter, R., Dosch, E., Utermann, G., & Dieplinger, H. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.9.1399 · Cited by 89
Self-citationKronenberg, F., Kuen, E., Ritz, E., Diaeresis]nig, P. K., Kraatz, G. D., Lhotta, K., Mann, J. F. E., Muller, G. A., Neyer, U., Riegel, W., et al. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v132461 · Cited by 88
Self-citationDyslipidemia and nephrotic syndrome: recent advances.
Kronenberg, F. (2005) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2004.10.003 · Cited by 85 · cited 1×
“There seems to be a gradual shift to the uremic lipid profile as kidney function deteriorates (19,20), which is further modified by concurrent illnesses such as diabetes (21) and nephrotic syndrome (22).”
BackgroundSelf-citationEvidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome.
De Sain-Van Der Velden, M. G., Reijngoud, D. J., Kaysen, G. A., Gadellaa, M. M., Voorbij, H., Stellaard, F., Koomans, H. A., & Rabelink, T. J. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v981474 · Cited by 85
Boes, E., Fliser, D., Ritz, E., König, P., Lhotta, K., Mann, J. F. E., Müller, G. A., Neyer, U., Riegel, W., Riegler, P., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005070733 · Cited by 84
Self-citationFellström, B., Zannad, F. M., Schmieder, R. E., Holdaas, H., Jardine, A. G., Rose, H., Wilpshaar, W., & the AURORA Study Group (2005) · Current Controlled Trials in Cardiovascular Medicine · doi:10.1186/1468-6708-6-9 · Cited by 81
DIEPEVEEN, S. H. A., VERHOEVEN, G. W. H. E., VAN DER PALEN, J., DIKKESCHEI, L. D., VAN TITS, L. J., KOLSTERS, G., OFFERMAN, J. J. G., BILO, H. J. G., & STALENHOEF, A. F. H. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01484.x · Cited by 80
Batista, M. C., Welty, F. K., Diffenderfer, M. R., Sarnak, M. J., Schaefer, E. J., Lamon‐Fava, S., Asztalos, B. F., Dolnikowski, G. G., Brousseau, M. E., & Marsh, J. B. (2004) · Metabolism · doi:10.1016/j.metabol.2004.05.001 · Cited by 78
Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure
Stenvinkel, P., Heimbürger, O., Tuck, C. H., & Berglund, L. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00880.x · Cited by 76
Ikewaki, K., Schaefer, J. R., Frischmann, M. E., Okubo, K., Hosoya, T., Mochizuki, S., Dieplinger, B., Trenkwalder, E., Schweer, H., Kronenberg, F., et al. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000188555.60475.c2 · Cited by 74
Self-citationThe effects of fibrates on lipoprotein and hemostatic coronary risk factors
Schonfeld, G. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90090-6 · Cited by 73
Small Apolipoprotein(a) Size Predicts Mortality in End-Stage Renal Disease: The CHOICE Study
Longenecker, J. C., Klag, M. J., Marcovina, S. M., Powe, N. R., Fink, N. E., Giaculli, F., & Coresh, J. (2002) · Circulation · doi:10.1161/01.cir.0000038946.91899.bb · Cited by 70
Guyard‐Dangremont, V., Lagrost, L., & Gambert, P. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40111-7 · Cited by 70
Wanner, C., Bahner, U., Mattern, R., Lang, D., & Passlick‐Deetjen, J. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh415 · Cited by 69
Kolodgie, F. D., Narula, J., Haider, N., & Virmani, R. (2001) · Cardiology Clinics · doi:10.1016/s0733-8651(05)70199-5 · Cited by 66
Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia
Knopp, R. H., Brown, W. V., Dujovne, C. A., Farquhar, J. W., Feldman, E. B., Goldberg, A. C., Grundy, S. M., Lasser, N. L., Mellies, M. J., Palmer, R. H., et al. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90871-0 · Cited by 65 · cited 1×
“These agents are effective in reducing plasma triglyceride concentrations and modestly increasing HDL cholesterol concentrations in the general population (115,116).”
BackgroundGene Therapy for Lipoprotein Lipase Deficiency: Working Toward Clinical Application
Rip, J., Nierman, M. C., Sierts, J. A., Petersen, W., Den Oever, K. V., Raalte, D. V., Ross, C. J. D., Hayden, M. R., Bakker, A. C., Dijkhuizen, P., et al. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1276 · Cited by 63
Hocher, B., Ziebig, R., Altermann, C., Krause, R., Asmus, G., Richter, C.-M., Slowinski, T., Sinha, P. K., & Neumayer, H. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000081662.64171.9b · Cited by 63
Bosch, T. P., Gahr, S., Belschner, U., Schaefer, C., Lennertz, A., Rammo, J., & for the DALI Study Group (2006) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2006.00336.x · Cited by 61
Winkelmayer, W. C., Charytan, D. M., Levin, R., & Avorn, J. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.10.009 · Cited by 59
Atherogenic Lipids and Lipoproteins in Hemodialysis Patients
Cheung, A. K., Wu, L., Kablitz, C., & Leypoldt, J. K. (1993) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)70318-9 · Cited by 58
Self-citationApolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure
Milionis, H. J., Elisaf, M., Tselepis, A. D., Bairaktari, E. T., Karabina, S., & Siamopoulos, K. C. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70147-2 · Cited by 58
Webb, A. T., Reaveley, D. A., O'Donnell, M., O'Connor, B., Seed, M., & Brown, E. A. (1995) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/10.3.354 · Cited by 58
Oi, K., Hirano, T., Sakai, S., Kawaguchi, Y., & Hosoya, T. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.07159.x · Cited by 56
Savdie, E., Gibson, J. C., Crawford, G. A., Simons, L. A., & Mahony, J. F. (1980) · Kidney International · doi:10.1038/ki.1980.196 · Cited by 55
Güz, G., Özdemir, F. N., Sezer, S., Işıklar, I., Arat, Z., Turan, M., & Haberal, M. A. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.17682 · Cited by 55
Why do we need a statin trial in hemodialysis patients?
Fellström, B., Holdaas, H., & Jardine, A. G. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s84.10.x · Cited by 52
Dieplinger, H., Zechner, R., & Kostner, G. M. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34369-8 · Cited by 52
Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients
Koda, Y., Nishi, S., Suzuki, M., & Hirasawa, Y. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.07167.x · Cited by 49
The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome
Kronenberg, F., Lingenhel, A., Lhotta, K., Rantner, B., Kronenberg, M. F., König, P., Thiery, J., Koch, M., von Eckardstein, A., & Dieplinger, H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00418.x · Cited by 47
Self-citationLemos, P. A., Serruys, P. W. J. C., de Feyter, P. J., Mercado, N. F., Goedhart, D. M., Saia, F., Arampatzis, C. A., Soares, P. R., Ciccone, M. M., Arquati, M., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.10.008 · Cited by 45
Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients
Ohashi, H., Oda, H., Ohno, M., Watanabe, S., & Sakata, S. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.07164.x · Cited by 44
Schwaiger, J. P., Lamina, C., Neyer, U., König, P., Kathrein, H., Sturm, W., Lhotta, K., Gröchenig, E., Dieplinger, H., & Kronenberg, F. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.01.011 · Cited by 42
Self-citationCsako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
The relationship between plasma apolipoprotein A-IV levels and coronary heart disease.
Mw, M., Guo, J., & Zhao, Y. (2001) · PubMed · Cited by 40
Kerschdorfer, L., König, P., Neyer, U., Bösmüller, C., Lhotta, K., Auinger, M., Hohenegger, M., Riegler, P., Margreiter, R., Utermann, G., et al. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00014-3 · Cited by 38
Self-citationWanner, C., Bartens, W., Walz, G., Nauck, M., & Schollmeyer, P. J. (1995) · Nephrology Dialysis Transplantation · doi:10.1093/oxfordjournals.ndt.a090858 · Cited by 38
Lins, R. L., Matthys, K. E., Billiouw, J. M., Dratwa, M., Dupont, P., Lameire, N. H., Peeters, P. C., Stolear, J.-C., Tielemans, C., Maes, B., et al. (2004) · Clinical Nephrology · doi:10.5414/cnp62287 · Cited by 35
Holdaas, H., Wanner, C., Abletshauser, C., Gimpelewicz, C. R., & Isaacsohn, J. L. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.06.003 · Cited by 33
Role of the kidney in the metabolism of apolipoprotein A-IV: influence of the type of proteinuria
Lingenhel, A., Lhotta, K., Neyer, U., Heid, I. M., Rantner, B., Kronenberg, M. F., König, P., von Eckardstein, A., Schober, M., Dieplinger, H., et al. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600178-jlr200 · Cited by 33
Self-citationAuguet, T., Sentı́, M., Rubiés-Prat, J., Pelegrí, A., Pedro‐Botet, J., Nogués, X., & Romero, R. (1993) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/8.10.1099 · Cited by 33
Plasma apolipoprotein A‐IV metabolism in patients with chronic renal disease
Dieplinger, H., Lobentanz, E., König, P., Graf, H., Sandholzer, C., Matthys, E. G. J., Rosseneu, M., & Utermann, G. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01822.x · Cited by 31
Apolipoprotein(a) Phenotype and Lipoprotein(a) Level Predict Peritoneal Dialysis Patient Mortality
Iliescu, E. A., Marcovina, S. M., Morton, A. R., Lam, M., & Koschinsky, M. L. (2002) · Peritoneal Dialysis International · doi:10.1177/089686080202200408 · Cited by 28
An increased apo A-IV serum concentration of patients with chronic renal failure on hemodialysis
Seishima, M., & Muto, Y. (1987) · Clinica Chimica Acta · doi:10.1016/0009-8981(87)90350-0 · Cited by 27
Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue
Haiman, M., Salvenmoser, W., Scheiber, K., Lingenhel, A., Rudolph, C., Schmitz, G., Kronenberg, F., & Dieplinger, H. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00519.x · Cited by 24
Self-citationApolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation
Kronenberg, F., Lhotta, K., König, P., Margreiter, R., Dieplinger, H., & Utermann, G. (2003) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201016 · Cited by 24
Self-citationGenetics and metabolism of lipoprotein(a) and clinical implications (Part 2).
Dieplinger, H., & Kronenberg, F. (1999) · PubMed · Cited by 20
Self-citationLipoprotein(a)-Associated Atherothrombotic Risk in Hemodialysis Patients
Emanuele, E., Lusignani, L. S., Peros, E., Montagna, G., D’Angelo, A., Montagna, L., & Geroldi, D. (2004) · American Journal of Nephrology · doi:10.1159/000077293 · Cited by 16
Árnadóttir, M. (1997) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365519709057813 · Cited by 15
Fazio, S., & Linton, M. F. (2003) · Molecular Interventions · doi:10.1124/mi.3.8.436 · Cited by 13
Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease
Kronenberg, F. (2004) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2.5.729 · Cited by 13
Self-citationHDL enhances oxidation of LDL in vitro in both men and women
Solakivi, T., Jaakkola, O., Salomäki, A., Peltonen, N., Metso, S., Lehtimäki, T. J., Jokela, H., & Nikkari, S. (2005) · Lipids in Health and Disease · doi:10.1186/1476-511x-4-25 · Cited by 13
Gazzaruso, C., Bonetti, G., Garzaniti, A., Pini, G. M., Ragazzoni, A., Bianchi, C. M., Jucci, A., Buscaglia, P., & Geroldi, D. (1996) · Nutrition Metabolism and Cardiovascular Diseases · Cited by 13
Kang, D., Yoon, K. I., Lee, S., Kang, S., Choi, K. H., Lee, H. Y., & Han, D. S. (1996) · Peritoneal Dialysis International · doi:10.1177/089686089601601s45 · Cited by 10
Götz, A., Böger, C. A., Hirschmann, C. M., Schmitz, G., Riegger, G. A. J., & Krämer, B. K. (2005) · PubMed · Cited by 7
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Graham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647
Authors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,334
Metadata
- Authors
- Kwan, B. C. H., Kronenberg, F., Beddhu, S., & Cheung, A. K.
- Affiliations
- Chinese University of Hong Kong (HK)
- Innsbruck Medical University (AT)
- Venue
- Journal of the American Society of Nephrology
- Published
- 2007-04
- Volume
- 18
- Issue
- 4
- Pages
- 1246-1261
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2132117066
- Cited by
- 354
- References
- 141
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 9 · 2023: 19 · 2022: 27 · 2021: 29 · 2020: 30 · 2019: 21 · 2018: 21 · 2017: 22 · 2016: 25 · 2015: 17 · 2014: 15 · 2013: 17 · 2012: 29
- FWCI
- 14.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Keywords
- chronic kidney disease, dyslipidemia, lipoprotein metabolism, lipid control, cardiovascular risk, cardiovascular outcomes
- MeSH terms
- Antioxidants, Cardiovascular Diseases, Chronic Disease, Renal Dialysis, Humans, Kidney Diseases, Lipoproteins, Niacin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.